Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason Yang

Showing results (121-130 of 128) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 128 results.
Nature Communications|August 7, 2023
Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targetingEric Hee Jun Lee, John P Murad, Lea Christian, et al.
Comparative Medicine|March 20, 2002
Contributions of mouse biology to breast cancer researchRobert D Cardiff, Howard A Bern, Leslie J Faulkin, et al.
Nature Medicine|February 1, 2024
First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 studyJin Li, Zhendong Chen, Yuxian Bai, et al.
Biorxiv : the Preprint Server for Biology|October 3, 2025
Atlas of Lysosomal Aging Reveals a Molecular Clock of Storage Disorder-Associated MetabolitesAnna M Puszynska, Thao P Nguyen, Andrew L Cangelosi, et al.
Nature Cancer|January 5, 2024
Author Correction: Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLCCaicun Zhou, Ziping Wang, Meili Sun, et al.
The Lancet. Oncology|January 17, 2022
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trialQing Zhou, Ming Chen, Ou Jiang, et al.
Nature Cancer|June 15, 2023
Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLCCaicun Zhou, Ziping Wang, Meili Sun, et al.
The Lancet. Oncology|June 16, 2025
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trialCaicun Zhou, Ziping Wang, Meili Sun, et al.
Pageof 13

Showing results (121-130 of 128) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 128 results.
Nature Communications|August 7, 2023
Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targetingEric Hee Jun Lee, John P Murad, Lea Christian, et al.
Comparative Medicine|March 20, 2002
Contributions of mouse biology to breast cancer researchRobert D Cardiff, Howard A Bern, Leslie J Faulkin, et al.
Nature Medicine|February 1, 2024
First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 studyJin Li, Zhendong Chen, Yuxian Bai, et al.
Biorxiv : the Preprint Server for Biology|October 3, 2025
Atlas of Lysosomal Aging Reveals a Molecular Clock of Storage Disorder-Associated MetabolitesAnna M Puszynska, Thao P Nguyen, Andrew L Cangelosi, et al.
Nature Cancer|January 5, 2024
Author Correction: Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLCCaicun Zhou, Ziping Wang, Meili Sun, et al.
The Lancet. Oncology|January 17, 2022
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trialQing Zhou, Ming Chen, Ou Jiang, et al.
Nature Cancer|June 15, 2023
Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLCCaicun Zhou, Ziping Wang, Meili Sun, et al.
The Lancet. Oncology|June 16, 2025
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trialCaicun Zhou, Ziping Wang, Meili Sun, et al.
Pageof 13